GlassScriptPhysician profile
David T Steele
NPI 1215348396
$46,507.63
in general payments reported to CMS, 2019-2025
39 companies · $24K in 2025
The $24K reported for 2025 was more than what 95% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $314 · 2020: $354 · 2021: $1,280 · 2022: $1,397 · 2023: $1,904 · 2024: $17K · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $33K · Food and Beverage: $6,600 · Travel and Lodging: $3,621 · Education: $178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $32,764.00 |
| Food and Beverage | $6,600.19 |
| Travel and Lodging | $3,620.93 |
| Education | $178.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $38,770.23 | 2020-2025 | Tremfya, Stelara, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,097.15 | 2019-2025 | Xifaxan, Trulance |
| Abbvie INC. | $1,367.41 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $733.31 | 2019-2025 | Entyvio |
| Celgene Corporation | $669.38 | 2021-2024 | Zeposia |
| Qol Medical, LLC | $381.19 | 2021-2025 | Sucraid, Sucraid |
| Pfizer INC. | $357.12 | 2020-2025 | |
| Lilly USA, LLC | $306.79 | 2025 | Omvoh |
| Ardelyx, INC. | $287.71 | 2022-2025 | Ibsrela |
| Genzyme Corporation | $165.99 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $146.37 | 2024-2025 | Voquezna |
| Gilead Sciences, INC. | $133.67 | 2021-2024 | |
| Celltrion USA INC. | $133.19 | 2024-2025 | Vegzelma, Zymfentra |
| Alexion Pharmaceuticals, INC. | $85.19 | 2019-2022 | |
| Intercept Pharmaceuticals, INC. | $84.60 | 2020-2024 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $77.72 | 2023-2024 | Dupixent |
| Daiichi Sankyo INC. | $71.16 | 2021-2025 | Injectafer |
| Ferring Pharmaceuticals INC. | $59.62 | 2021-2025 | Rebyota |
| Alnylam Pharmaceuticals INC. | $58.41 | 2022-2023 | Givlaari |
| Nestle Healthcare Nutrition INC. | $57.65 | 2021-2023 | |
| Redhill Biopharma INC. | $53.06 | 2020-2022 | |
| Amgen INC. | $44.88 | 2020-2021 | |
| Ipsen Biopharmaceuticals, INC | $44.07 | 2025 | Iqirvo |
| Evoke Pharma, INC. | $41.81 | 2021-2023 | Gimoti |
| Braintree Laboratories, INC. | $37.16 | 2022-2024 | Sutab, Suflave |
| Bayer Healthcare Pharmaceuticals INC. | $30.96 | 2019 | |
| Merck Sharp & Dohme LLC | $30.49 | 2021-2022 | |
| Conmed Corporation | $25.91 | 2024 | Conmed Biliary, Conmed Hemostasis |
| Pharmacosmos Therapeutics INC. | $23.26 | 2023 | Monoferric |
| Mylan Institutional INC. | $22.16 | 2023 | Hulio |
| Aimmune Therapeutics, INC. | $20.44 | 2025 | Zenpep |
| Madrigal Pharmaceuticals | $18.90 | 2025 | Rezdiffra |
| Organon LLC | $16.84 | 2023 | Hadlima |
| Exact Sciences Corporation | $15.27 | 2024 | Cologuard Collection Kit |
| Capsovision, INC. | $15.11 | 2023 | Capsocam Plus |
| Medtronic, INC. | $13.68 | 2021 | |
| Ambu INC. | $9.77 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Steele listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.